Perrigo Company PLC
http://www.perrigo.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Perrigo Company PLC
Tech Transfer Roundup: Athenex, PDS Align With National Cancer Institute On Oncology R&D
Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.
Consolidation And COVID See Off-Patent Industry Rankings Rewritten
After an extraordinary year that saw demand patterns and the supply chain upended by the COVID-19 pandemic, as well as a major merger that has transformed one of the global off-patent industry’s biggest players, Generics Bulletin’s Top 50 has once again seen significant changes.
Consumer Health Changes ‘At Speed Of Instagram’ Drive J&J’s Decision On Separating Businesses
J&J provided color on plans for standalone consumer health business during a business overview with analysts. Multiple separation pathways are being considered.
Perrigo Suffers As It Waves Goodbye To Rx
Perrigo CEO Murray Kessler has acknowledged “disappointing” third quarter results for the company during a transitional quarter that saw it finally divest its Rx prescription generics business ahead of its upcoming acquisition of consumer healthcare specialist HRA Pharma.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
- OTC, Consumer
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Agis Industries
- Chemagis
- Clay-Park Labs
- Cobrek Pharmaceuticals
- Elan Corporation
- JB Laboratories
- Onclave Therapeutics Limited
- Omega Pharma Invest N.V.
- Paddock Laboratories
- Omega Pharma Invest N.V.
- Ranir Global Holdings LLC
- Rosemont Pharmaceuticals Ltd.
- Unico Holdings Inc.
- Velcera, Inc.
- Geiss, Destin & Dunn, Inc.
- High Ridge Brands